Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by BTIG Research

Analysts at BTIG Research started coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report issued on Monday,Benzinga reports. The firm set a “buy” rating and a $23.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 130.46% from the stock’s previous close.

ZVRA has been the subject of a number of other research reports. Wall Street Zen lowered shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings raised shares of Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a report on Tuesday, March 10th. HC Wainwright set a $26.00 price target on Zevra Therapeutics in a report on Tuesday, December 30th. Finally, Guggenheim set a $23.00 price target on Zevra Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 10th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Zevra Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

Zevra Therapeutics Stock Down 2.1%

Shares of NASDAQ ZVRA opened at $9.98 on Monday. The company has a debt-to-equity ratio of 0.40, a current ratio of 5.68 and a quick ratio of 5.63. The stock has a market capitalization of $585.93 million, a PE ratio of 7.50 and a beta of 0.91. Zevra Therapeutics has a one year low of $6.19 and a one year high of $13.16. The business’s fifty day moving average price is $8.93 and its 200-day moving average price is $9.09.

Insider Activity

In other Zevra Therapeutics news, SVP Timothy J. Sangiovanni sold 3,000 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $9.18, for a total value of $27,540.00. Following the completion of the transaction, the senior vice president directly owned 29,590 shares of the company’s stock, valued at $271,636.20. This trade represents a 9.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Neil F. Mcfarlane sold 91,000 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $9.38, for a total transaction of $853,580.00. Following the transaction, the chief executive officer owned 364,350 shares of the company’s stock, valued at $3,417,603. This trade represents a 19.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 114,158 shares of company stock worth $1,062,878. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC raised its stake in Zevra Therapeutics by 399.5% in the third quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after purchasing an additional 2,297 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Zevra Therapeutics by 30.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after buying an additional 1,280 shares during the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in shares of Zevra Therapeutics in the 4th quarter worth $53,000. Russell Investments Group Ltd. raised its position in shares of Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after buying an additional 4,475 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after acquiring an additional 8,552 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.